Safe use of the CXCR4 inhibitor ALX40-4C in humans

AIDS Research and Human Retroviruses

Volumn 17, Issue 6, 2001, Pages 475-486

  Doranz, Benjamin J ^a   Filion, Lionel G ^b   Diaz Mitoma, Francisco ^b   Sitar, Daniel S ^c   Sahai, Jan ^d,e   Baribaud, Frédéric ^a   Orsini, Michael J ^f,g   Benovic, Jeffrey L ^f   Cameron, William ^b,d   Doms, Robert W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Glaxo Wellcome Inc   (Canada)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENT; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SCREENING; DRUG TOLERANCE; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS STRAIN; VIRUS TYPING;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CONSUMER PRODUCT SAFETY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RECEPTORS, CXCR4;

EID: 0034915564     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220151126508     Document Type: Article

References (53)

1. Unwelcome guests with master keys: How HIV uses chemokine receptors for cellular entry
2. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
3. Coreceptors for HIV-1 entry
4. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
5. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR5
6. Evidence for cell-surface association between Fusin and the CD4-gp120 complex in human cell lines
7. A new classification for HIV-1
8. Coreceptor use by primate lentiviruses
9. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene
10. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
11. Genetic resistance of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
12. HIV-1 infection in an individual homozygous for the CCR5 deletion allele
13. HIV-1 infection in a man homozygous for CCR5Δ32
14. HIV-1 infection in an individual homozygous for CCR5Δ32
15. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5Δ32
16. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1
17. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development
18. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract
19. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4
20. The chemokine SDF-1 is a chemoattractant for human CD341+ hematopoietic cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood
21. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation
22. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques
23. Antiherpetic activities of N-α-acetyl-nona-D-arginine amide acetate
24. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
25. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions
26. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
27. Development of an enzyme-linked immunosorbent assay for measurement of serum-associated ALX40-4C
28. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions
29. Trafficking of the HIV coreceptor CXCR4
30. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by super-infection of nonproductively infected cell lines with recombinant luciferase-encoding viruses
31. Vpr is required for efficient replication of human imunodeficiency virus type-1 in mononuclear phagocytes
32. HIV coreceptor down-regulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication
33. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
34. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains
35. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity
36. A small-molecule, non-peptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
37. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
38. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
39. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop
40. The ability of HIV type 1 to use CCR3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR5-tropic V3 loop
41. Identification of determinants on a dual-tropic human immunodeficiency virus type-1 envelope glycoprotein that confer usage of CXCR4
42. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization
43. Human immunodeficiency virus type I envelope determinants of the CCR2b, CCR3, STRL33, and APJ coreceptors
44. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency type 1 primary isolate
45. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
46. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor
47. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4
48. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection
49. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
50. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation
51. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
52. Will multiple coreceptors need to be tar-geted by inhibitors of human immunodeficiency virus type 1 entry?
53. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and preven-tion of emergence of the syncytium-inducing phenotype by blockade of CXCR4